Results 61 to 70 of about 95,511,506 (302)
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Dagstuhl Reports, Table of Contents, Volume 8, Issue 10, 2018
Dagstuhl Reports, Table of Contents, Volume 8, Issue 10 ...
core +1 more source
Dagstuhl Reports, Table of Contents, Volume 9, Issue 10, 2019
Dagstuhl Reports, Table of Contents, Volume 9, Issue 10 ...
core +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Identità Differenze Conflitti
Volume collettaneo che raccoglie gli interventi e i contributi del Convegno "Identità Differenze Conflitti" tenutosi a Venezia nel settembre 2007 a conclusione del PRIN 2004 (resp. naz. e loc. prof. L. Ruggiu)
Mora, Francesco +4 more
core
Dagstuhl Reports, Volume 1, Issue 10, October 2011, Complete Issue
Dagstuhl Reports, Volume 1, Issue 10, October 2011, Complete ...
core +1 more source
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source

